Client News

Posted: September 19, 2014, 10:02 pm
Posted: September 19, 2014, 10:02 pm
[AP] - A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: Ohr Pharmaceutical fell 32.1 percent to $7.74. Web.com Inc. fell 19.9 percent to $27.70. Aemetis Inc. fell 12.5 percent ...
Posted: September 19, 2014, 10:02 pm
Posted: September 19, 2014, 10:02 pm
[GlobeNewswire] - TEL AVIV, Israel -- Alcobra Ltd. , an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity ...
Posted: September 19, 2014, 8:21 pm
Posted: September 19, 2014, 5:04 pm
[Thomson Reuters ONE] - PRESS RELEASE Cynapsus Therapeutics Announces Change of Auditor September 19, 2014 TORONTO - Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company") (TSX-V: CTH) (OTCQX: CYNAF) announces ...
Posted: September 19, 2014, 12:02 pm
[Marketwired] - Cynapsus Therapeutics Inc. announces that it has changed its auditor. McGovern, Hurley, Cunningham, LLP has resigned at the request of the Company, effective September 18, 2014. The Directors of the Company ...
Posted: September 19, 2014, 12:00 pm
[Business Wire] - Navidea Biopharmaceuticals, Inc. today announced that Lymphoseek® Injection has been granted Orphan Drug Designation by the U.S. Food & Drug Administration for use in sentinel lymph node detection in patients with cancer of the head and neck.
Posted: September 18, 2014, 8:07 pm
Posted: September 18, 2014, 5:04 pm
Posted: September 18, 2014, 12:10 pm
[PR Newswire] - "Immune" or "the Company") announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC). Dr. Daniel Teper, Chairman and CEO of Immune comments: "Bertilimumab is among the first biologic drugs for auto-immune diseases with a biomarker strategy. We look forward to the results of this Phase II proof of concept clinical trial in Ulcerative Colitis as well as the previously initiated Phase II clinical trial in Bullous Pemphigoid, an orphan auto-immune disease of the skin."
Posted: September 18, 2014, 6:30 am
[GlobeNewswire] - COPPELL, Texas -- ZS Pharma , a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that management will present at the 21st ...
Posted: September 17, 2014, 8:00 pm